Vicriviroc/MK 2048

Drug Profile

Vicriviroc/MK 2048

Alternative Names: MK 2048/MK 4176; MK 2048/vicriviroc; MK 2048A IVR; MK 4176/MK 2048; VCV/MK 2048

Latest Information Update: 27 Jul 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases
  • Class Naphthyridines; Piperazines; Pyrimidines; Pyrimidinones
  • Mechanism of Action CCR5 receptor antagonists; HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 17 Jul 2015 National Institute of Allergy and Infectious Diseases initiates enrolment in a phase I trial for HIV infections (Prevention, In volunteers) in USA (NCT02419456)
  • 18 Jun 2015 Phase-I clinical trials in HIV infections (Prevention, In volunteers) in USA (Vaginal) (NCT02356302)
  • 23 Apr 2015 National Institute of Allergy and Infectious Diseases plans a phase I trial for HIV infections (Prevention, In volunteers) in USA (NCT02356302)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top